Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026. CEO David Weinstein described the company’s proprietary AI platform for accelerating therapeutic discovery in CNS disorders and strengthening biodefense preparedness.

The platform integrates multimodal biological datasets, advanced machine learning, and in vivo validation to identify targets, optimize candidates, and compress development timelines. The company said it is advancing discussions with pharmaceutical firms and government agencies about its biotech and biodefense capabilities.

Market Reaction

-11.82% $0.72 1.7x vol

15m delay 2 alerts

-11.82% Since News

$0.72 Last Price

$0.68 $0.78 Day Range

-$2M Valuation Impact

$17M Market Cap

1.7x Rel. Volume

Following this news, LNAI has declined 11.82%, reflecting a significant negative market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.72. This price movement has removed approximately $2M from the company's valuation. Trading volume is above average at 1.7x the average, suggesting increased trading activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

AUD patients: ~30 million individuals Untreated AUD share: ~95% AUD economic cost: ~$250 billion +5 more

8 metrics

AUD patients ~30 million individuals Estimated U.S. population affected by Alcohol Use Disorder

Untreated AUD share ~95% AUD-affected individuals receiving no effective pharmacologic treatment

AUD economic cost ~$250 billion Annual U.S. economic cost related to Alcohol Use Disorder

AI-drug revenue tailwind $240 billion Estimated revenue-at-risk tailwind cited for AI drug discovery deals

External innovation capital ~$1.3 trillion Capital pool cited for external innovation in AI-enabled drug discovery

Shares sold short ~11 million shares Short position vs post-split float of ~23 million shares

AChE model AUROC 0.94 AUROC Performance of AI model distinguishing active AChE inhibitors

Alzheimer’s diagnostic lift 35% improvement Improvement in diagnostic accuracy vs MRI alone in Alzheimer’s program

Market Reality Check

Price: $0.8179 Vol: Volume 100,378 is 0.37x t...

low vol

$0.8179 Last Close

Volume Volume 100,378 is 0.37x the 20-day average of 270,823, indicating subdued trading interest pre‑news. low

Technical Shares trade below the 200-day MA of 1.04 at a price of 0.8179, reflecting a longer-term downtrend.

Peers on Argus

No peers from the Pharmaceutical Preparations sector appeared in the momentum sc...

No peers from the Pharmaceutical Preparations sector appeared in the momentum scanner, suggesting this AI/biodefense media feature is being priced as company-specific rather than part of a sector rotation.

Previous AI Reports

4 past events · Latest: Jan 27 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 27	AI safeguard launch	Positive	-2.0%	Launch of Sentinel AI safeguard to block generation of novel chemical threats.
Jan 26	AI AUD program	Positive	-2.5%	NIH-backed AI program expanded into commercial Alcohol Use Disorder drug discovery.
Oct 30	AI neurotoxicity data	Positive	-2.0%	AI platform results for detecting acetylcholinesterase-targeting neurotoxic compounds.
Oct 06	AI Alzheimer’s launch	Positive	-1.6%	Launch of AI-powered Alzheimer’s program with improved diagnostic accuracy claims.

Pattern Detected

Recent AI-tag news has consistently been followed by modest negative price reactions despite positive platform updates.

Recent Company History

Over the past several months, Lunai Bioworks has repeatedly highlighted its AI platform across neurodegeneration and biodefense. AI-tag announcements on Oct 6, 2025, Oct 30, 2025, Jan 26, 2026, and Jan 27, 2026 showcased advances in Alzheimer’s diagnostics, neurotoxic compound detection, NIH-backed alcohol use disorder discovery, and the Sentinel biosecurity safeguard. Despite these seemingly positive developments, each event saw a small negative next-day move, indicating a pattern where AI updates have not yet driven sustained upside.

Historical Comparison

-2.0% avg move · Past AI-tag announcements saw an average next-day move of -2.01%. This CNBC feature continues the AI...

AI

-2.0%

Average Historical Move AI

Past AI-tag announcements saw an average next-day move of -2.01%. This CNBC feature continues the AI platform story, providing broader visibility against a backdrop of historically muted to negative price follow-through.

AI-tag history shows progression from Alzheimer’s diagnostics and neurotoxicity detection to NIH-backed AUD discovery and the Sentinel safeguard, with today’s CNBC segment emphasizing broader AI-driven CNS and biodefense positioning.

Market Pulse Summary

The stock is dropping -11.8% following this news. A negative reaction despite upbeat CNBC coverage w...

Analysis

The stock is dropping -11.8% following this news. A negative reaction despite upbeat CNBC coverage would fit the pattern of prior AI-tag news, which saw an average next-day move of -2.01%. Past platform and program launches often coincided with modest declines, suggesting market skepticism toward early-stage AI narratives. In such a scenario, attention would likely focus on whether concrete pharma partnerships or government contracts emerge to validate the exposure and offset sentiment pressure.

Key Terms

biodefense, machine learning, in vivo

3 terms

biodefense medical

"an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute."

Biodefense is the set of tools, technologies and services designed to detect, prevent or respond to biological threats such as infectious diseases, engineered pathogens or accidental releases. For investors it signals a market focused on diagnostics, vaccines, protective gear, and rapid response systems — similar to an alarm-and-firefighting network for biological risks — which can drive revenue growth, government contracts and regulatory scrutiny depending on outbreak risks and public policy priorities.

machine learning technical

"integrates multimodal biological datasets, advanced machine learning, and in vivo validation"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

in vivo medical

"advanced machine learning, and in vivo validation systems to rapidly identify novel targets"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

AI-generated analysis. Not financial advice.

SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness.

"We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently."

During the national segment, Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across complex neurological disorders and emerging chemical and biological threat countermeasures.

The CNBC appearance underscores growing investor attention on scalable AI platforms transforming central nervous system therapeutics and national security–focused biodefense innovation. Highlights of the interview aired on Business Minute can be watched via the following link:

https://www.linkedin.com/posts/lunai-bioworks_were-proud-to-share-that-our-client-lunai-activity-7427770187589877760-hp3X

Lunai is actively advancing discussions with leading pharmaceutical companies and government agencies around both their biotech and biodefense capabilities.

About Lunai Bioworks
Lunai Bioworks (NASDAQ: LNAI) is an AI-powered biotech and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats. For more information, visit https://lunaibioworks.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding potential clinical impact, therapeutic benefit, development timelines, partnering strategy, and commercial value. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Lunai Bioworks undertakes no obligation to update forward-looking statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-highlights-drug-discovery-and-biodefense-ai-platform-on-cnbc-302687672.html

SOURCE Lunai Bioworks Inc.

FAQ

What did Lunai Bioworks (LNAI) announce on CNBC on Feb 13, 2026?

They highlighted use of a proprietary AI platform to accelerate CNS drug discovery and biodefense programs. According to the company, CEO David Weinstein explained multimodal data, machine learning, and in vivo validation are used to speed target ID and candidate optimization.

How does Lunai Bioworks (LNAI) say its AI platform speeds drug discovery?

It speeds discovery by integrating multimodal biological datasets with advanced machine learning and in vivo validation. According to the company, this combination aims to identify novel targets, optimize candidates, and compress development timelines across complex neurological disorders.

What biodefense capabilities did Lunai Bioworks (LNAI) describe on CNBC?

They described AI-driven countermeasure discovery for emerging chemical and biological threats. According to the company, the platform is applied to biodefense preparedness by rapidly identifying targets and advancing threat-specific therapeutics and validations.

Is Lunai Bioworks (LNAI) partnering with pharma or government after the CNBC appearance?

The company said it is actively advancing discussions with leading pharmaceutical companies and government agencies. According to the company, those talks concern both its biotech therapeutic work and national security–focused biodefense capabilities.

Who spoke for Lunai Bioworks (LNAI) on CNBC and what was emphasized?

CEO David Weinstein spoke and emphasized deploying AI to accelerate CNS discovery and biodefense preparedness. According to the company, he highlighted precision biology, reduced development risk, and scaling high-impact therapeutic programs more efficiently.